Palvella Therapeutics, Inc. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2022-11-04: Form 10-Q; Exhibit 10.2; Description Amendment No. 5, dated August 1, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB..
- 2022-11-04: Form 10-Q; Exhibit 10.1; Description Separation Agreement by and between Pieris Pharmaceuticals, Inc. and Tim Demuth, M.D., dated as of August 4, 2022..
- 2022-08-04: Form 10-Q; Exhibit 10.3; Description Amendment No. 4, dated June 30, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB..
- 2022-08-04: Form 10-Q; Exhibit 10.2; Description Amendment No. 3, dated June 9, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB..
| Filed | Form | Exhibit | Description |
|---|
| 2022-11-04 | 10-Q | 10.2 | Amendment No. 5, dated August 1, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB. |
|---|
| 2022-11-04 | 10-Q | 10.1 | Separation Agreement by and between Pieris Pharmaceuticals, Inc. and Tim Demuth, M.D., dated as of August 4, 2022. |
|---|
| 2022-08-04 | 10-Q | 10.3 | Amendment No. 4, dated June 30, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB. |
|---|
| 2022-08-04 | 10-Q | 10.2 | Amendment No. 3, dated June 9, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB. |
|---|
| 2022-06-27 | 8-K | 10.1 | Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as Amended. |
|---|
| 2022-05-11 | 10-Q | 10.1 | Employment Contract by and between Pieris Pharmaceuticals GmbH and Tim Demuth, M.D., Ph.D., dated as of August 1, 2021 |
|---|
| 2022-03-02 | 10-K | 10.39 | Non-Employee Director Compensation Policy, as amended |
|---|